06 August 2018
Visiongain’ has launched a new pharma report Global Pharmaceutical Excipients Market Forecast to 2027: Plant-Based, Animal Chemistry, Mineral, Synthetic, Oral Application, Topical Application, Parental Application, Other Application, Binders, Diluents, Glidants, Disintegrant, Others
The pharmaceutical industry is facing various challenges such as patent cliff, strict regulations and reduced healthcare spending; all these factors are hindering the development of new drugs. Novel excipients offer several opportunities to overcome these challenges. Novel excipients can be used to reformulate approved drugs and also improve the quality and safety of the drugs as well as reducing manufacturing cost. Manufacturers of generic drugs are now mainly focusing on reformulating and reintroducing their products with a cost-effective process to develop super generic drugs and to extent patents. Hence, various important steps are taken by key players such as modification in design and dosage forms, increasing focus on quality by design, and use of excipients in reformulation of drugs.
The lead analyst of the report commented “Pharmaceutical industry is highly dependent on the development and discovery of new molecules for the replacement of old drugs revenue stream that are going towards patent expiry. Therefore, drug formulators and innovators are mainly focusing on developing new chemical entities. Similarly, narrow pipeline of new chemical excipients, increasing preference of manufacturers for the direct compression (DC) process and technological advancement in tablets manufacturing, are some of the other factors that will give opportunity for the development of high-functionality excipients.”
Leading companies featured in the report include Evonik Industries AG, BASF SE, Innophos Holdings Inc., The Lubrizol Corporation, The DOW Chemical Company, Wacker Chemie AG, Ashland Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth